Production (Stage)
Cellectar Biosciences, Inc.
CLRB
$0.3822
-$0.031-7.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 75.21% | 70.11% | 16.30% | 90.97% | -270.52% |
| Total Depreciation and Amortization | -36.38% | -2.00% | 66.50% | 70.54% | 107.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -94.03% | -154.26% | -63.03% | -586.75% | 1,692.70% |
| Change in Net Operating Assets | -67.82% | -104.02% | 200.24% | -852.63% | -339.90% |
| Cash from Operations | 29.77% | -13.73% | -13.62% | -87.80% | -86.00% |
| Capital Expenditure | -- | 77.02% | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 77.02% | 100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | 4,937.66% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | -21.94% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -130.80% | -16.49% | -39.32% | -88.09% | 524.10% |